It is yet another de-SPAC disaster.
A pharmaceutical company that last week completed its merger with a blank-check company sponsored by two prominent hedge fund firms is the latest company to have its stock mauled.
Shares of EQRx closed Tuesday at $6.41, down more than 21 percent on the day and more than 35 percent since the stock began trading last Friday, following the company’s merger with CM Life Sciences III.
